Claire Saffery

Royal Marsden NHS Foundation Trust — United Kingdom

Medicine · Health Sciences

10h-index1.5kcitations35works4.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Colorectal Cancer Treatments and Studies(16), Gastric Cancer Management and Outcomes(15), Cancer Genomics and Diagnostics(10), Esophageal Cancer Research and Treatment(8), Lung Cancer Treatments and Mutations(6)

Publications35 total

Single agent olaparib in advanced oesophago-gastric cancer: Primary results from the SOlar clinical phase II single arm trial.
Journal of Clinical Oncology·2025
Phase II trial of domatinostat (4SC-202) in combination with avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colorectal adenocarcinoma: EMERGE
ESMO Open·2024· 9 citedOpen Access
Supplementary Data from MRI Tumor Regression Grade and Circulating Tumor DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal Cancer
2023Open Access
Data from MRI Tumor Regression Grade and Circulating Tumor DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal Cancer
2023Open Access
Data from MRI Tumor Regression Grade and Circulating Tumor DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal Cancer
2023Open Access
Supplementary Data from MRI Tumor Regression Grade and Circulating Tumor DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal Cancer
2023Open Access
1226P Predicting benefit from maintenance durvalumab after first-line chemotherapy (1L CTx) in oesophagogastric adenocarcinoma (OGA) using a novel tumour microenvironment (TME) RNA-based assay
Annals of Oncology·2022· 2 citedOpen Access
443P EMERGE: A phase II trial assessing the efficacy of domatinostat plus avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colorectal cancers – phase IIA dose finding
Annals of Oncology·2021· 6 cited
Diagnostic Accuracy and Safety of Coaxial System in Oncology Patients Treated in a Specialist Cancer Center With Prospective Validation Within Clinical Trial Data
Frontiers in Oncology·2020· 5 citedOpen Access
P-138 A comparison of the transcriptomic profiles of matched tissue from primary colorectal cancer and corresponding secondary lung metastases
Annals of Oncology·2020· 1 cited
Diagnostic accuracy and safety of coaxial core-needle biopsy (CNB) system in Oncology patients treated in a specialist cancer centre with prospective validation within clinical trial data
2020· 1 citedOpen Access
SOlar: A translational phase II study of single-agent olaparib in the treatment of advanced esophagogastric cancer.
Journal of Clinical Oncology·2020· 1 cited
MRI Tumor Regression Grade and Circulating Tumor DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal Cancer
Clinical Cancer Research·2019· 133 cited
EMERGE: Epigenetic modulation of the immune response in gastrointestinal cancers
Annals of Oncology·2019· 4 citedOpen Access
CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids
Journal for ImmunoTherapy of Cancer·2019· 110 citedOpen Access
Additional file 1: of CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids
Figshare·2019Open Access
Rash, neutrophil-lymphocyte ratio (NLR) and survival in the REAL3 trial
Annals of Oncology·2017· 1 cited
Clinical and pre-clinical biomarkers of Regorafenib (REG) efficacy in metastatic colorectal cancer (mCRC) in a phase II trial
Annals of Oncology·2017
PLATFORM: Planning treatment of oesophago-gastric (OG) cancer—A randomised maintenance therapy trial.
Journal of Clinical Oncology·2016· 6 cited
A prospective translational study investigating molecular predictors of resistance and response to regorafenib (REG) monotherapy in RAS mutant (mt) metastatic colorectal cancer (mCRC): Initial magnetic resonance imaging (MRI) sub-study result.
Journal of Clinical Oncology·2016
page 1 of 2Next →

Frequent Co-authors

David Cunningham(35), Ian Chau(33), Naureen Starling(22), Andrew Wotherspoon(15), Ruwaida Begum(12), David Watkins(12), Nicola Valeri(10), Yolanda Barbáchano(9), Katharina von Loga(9), Sheela Rao(9), Alicia Okines(8), Nicos Fotiadis(8), Gina Brown(7), Isma Rana(7), Michael Hubank(7), Marco Gerlinger(7), Gary Middleton(6), Jonathan Wadsley(6), Clare Peckitt(6), Shelize Khakoo(6)